Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Alnylam PharmaceuticalsALNY | Open-market sale10b5-1 plan | 06/01 | 06/03 | 3,830 sh5 trades | $299.18avg. | $1,145,852.75 | −70.8% | |
Alnylam PharmaceuticalsALNY | Open-market sale10b5-1 plan | 04/02–04/06 | 04/07 | 3,910 sh14 trades | $325.92avg. | $1,274,342.99 | −29.3% | |
Alnylam PharmaceuticalsALNY | Open-market sale10b5-1 plan | 03/04–03/05 | 03/06 | 4,713 sh12 trades | $323.53avg. | $1,524,795.55 | −20.1% | |
Alnylam PharmaceuticalsALNY | Open-market sale10b5-1 plan | 03/04–03/05 | 03/06 | 1,291 sh12 trades | $323.54avg. | $417,685.48 | −5.9% | |
Alnylam PharmaceuticalsALNY | Open-market sale | 03/04 | 03/06 | 2,933 sh8 trades | $323.08avg. | $947,580.95 | −3.0% | |
Alnylam PharmaceuticalsALNY | Open-market sale | 03/04 | 03/06 | 2,468 sh8 trades | $323.08avg. | $797,350.54 | −3.8% | |
Alnylam PharmaceuticalsALNY | Open-market sale | 03/04 | 03/06 | 2,309 sh8 trades | $323.08avg. | $745,983.83 | −6.3% | |
Alnylam PharmaceuticalsALNY | Open-market sale10b5-1 plan | 03/02–03/03 | 03/04 | 3,492 sh14 trades | $323.63avg. | $1,130,131.45 | −13.0% | |
Alnylam PharmaceuticalsALNY | Open-market sale10b5-1 plan | 03/02–03/03 | 03/04 | 3,250 sh14 trades | $323.62avg. | $1,051,773.01 | −12.9% | |
Alnylam PharmaceuticalsALNY | Open-market sale | 03/02 | 03/04 | 6,799 sh10 trades | $327.65avg. | $2,227,698.49 | −6.4% | |
Alnylam PharmaceuticalsALNY | Open-market sale | 03/02 | 03/04 | 2,206 sh10 trades | $327.65avg. | $722,800.78 | −3.3% | |
Alnylam PharmaceuticalsALNY | Open-market sale | 03/02 | 03/04 | 1,598 sh10 trades | $327.65avg. | $523,583.78 | −4.2% | |
Alnylam PharmaceuticalsALNY | Open-market sale10b5-1 plan | 02/27 | 03/02 | 4,627 sh5 trades | $331.34avg. | $1,533,099.58 | −17.3% | |
Alnylam PharmaceuticalsALNY | Open-market sale10b5-1 plan | 02/13–02/17 | 02/17 | 4,000 sh2 trades | $321.24avg. | $1,284,977.08 | −15.8% | |
Alnylam PharmaceuticalsALNY | Open-market sale | 02/13 | 02/17 | 6,958 sh | $310.08 | $2,157,536.64 | −7.5% | |
Jeffrey V. PoultonEVP, CFO | Alnylam PharmaceuticalsALNY | Open-market sale | 02/13 | 02/17 | 2,242 sh | $310.08 | $695,199.36 | −3.6% |
Garg PushkalEVP Chief R&D | Alnylam PharmaceuticalsALNY | Open-market sale | 02/13 | 02/17 | 2,242 sh | $310.08 | $695,199.36 | −8.3% |
Tolga TangulerEVP, Chief Commercial Officer | Alnylam PharmaceuticalsALNY | Open-market sale | 02/13 | 02/17 | 1,959 sh | $310.08 | $607,446.72 | −5.8% |
Alnylam PharmaceuticalsALNY | Open-market sale10b5-1 plan | 01/12–01/13 | 01/14 | 3,800 sh27 trades | $367.37avg. | $1,395,992 | −15.2% | |
Alnylam PharmaceuticalsALNY | Open-market sale | 01/12 | 01/14 | 9,577 sh21 trades | $362.86avg. | $3,475,156.51 | −10.9% |